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Abstract
A rat model was used to study the effects of cirrhosis on antibiotic therapy of pneumococcal pneumonia. Cirrhotic and control male
Sprague-Dawley rats were infected transtracheally with type 3 Streptococcus pneumoniae. Treatment began 18 h later with phosphate-
buffered saline (PBS), azithromycin (50 mg/kg), trovafloxacin (50 mg/kg), or ceftriaxone (100 mg/kg) injected subcutaneously twice daily
for 5 days. Antibiotic concentrations were measured by high-performance liquid chromatography. Azithromycin, trovafloxacin, and
ceftriaxone were all equally effective at preventing mortality in both cirrhotic and normal rats. Free fraction area under the curve to minimum
inhibitory concentration ratio (AUC/MIC) and maximum calculated serum concentration to MIC ratio (Cmax/MIC) and percent time that the
serum concentration exceeded the MIC (%T N MIC) were greater for ceftriaxone compared with azithromycin or trovafloxacin.
Azithromycin achieved higher concentrations in bronchoalveolar lavage fluid (BALF), epithelial lining fluid (ELF), and BAL white blood
cells than ceftriaxone or trovafloxacin in cirrhotic rats. Macrolide, h-lactam, or fluoroquinolone antibiotic efficacy in a pneumococcal
pneumonia model does not appear to be affected by hepatic cirrhosis.
Published by Elsevier Inc.
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1. Introduction
Streptococcus pneumoniae (pneumococcus) is the most
common bacterial cause of adult pneumonia (File, 2003).
Individuals with alcohol-induced cirrhosis are at increased
risk for severe pneumococcal infections, including bacter-
emia (Austrian and Gold, 1964; Mufson et al., 1974). The
associated mortality can exceed 50% in patients with severe
liver disease even with the use of appropriate antimicrobial
therapy (Gransden et al., 1985). Despite the association
between cirrhosis and severity of infection, the effect of
liver impairment on antibiotic penetration into pulmonary
tissues and the outcome of specific forms of antibiotic
treatment of pneumococcal disease are unknown (Bergman
et al., 1999).
Ceftriaxone, an expanded-spectrum cephalosporin, is
approved for therapy of pneumococcal infections, including
pneumonia, bacteremia, and meningitis. It is effective and
widely used for infections known or suspected to be caused by
penicillin-resistant pneumococci (Kaplan and Mason, 1998).
The macrolide derivative, azithromycin, has excellent in
vitro antibiotic activity against a variety of lower respiratory
tract pathogens, including S. pneumoniae (Zhanel et al.,
2001). Pharmacokinetic studies in animals, including rats,
have shown that azithromycin has an extended half-life and
excellent penetration into lung tissue after oral (Girard et al.,
1987) or parenteral (Shepard and Falkner, 1990) adminis-
tration. Similarly, healthy human volunteers who received
oral azithromycin had sustained lung tissue penetration and
extensive accumulation in alveolar macrophages after 5 oral
doses (Olsen et al., 1996).
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Alatrofloxacin is an l-alanyl-l-alanine prodrug that is
rapidly cleaved in vivo to the parent fluoroquinolone,
trovafloxacin (Brighty and Gootz, 1997). Trovafloxacin, an
advanced generation fluoroquinolone, has excellent in vitro
and in vivo activity against a variety of bacterial respiratory
pathogens, including penicillin-resistant pneumococci
(Eliopoulos et al., 1993; Kim et al., 1997; Thomson et
al., 1997). Pharmacokinetic studies in animals, including
rats, have shown that trovafloxacin has an extended half-life
and excellent penetration into pulmonary tissue after oral or
parenteral administration (Teng et al., 1996a, 1996b). In a
murine model of pneumococcal pneumonia, trovafloxacin
was more effective than temafloxacin or ciprofloxacin and
achieved excellent concentrations in lung tissue (Girard et al.,
1995). Concentrations of trovafloxacin in bronchial mucosa,
epithelial lining fluid (ELF), alveolar macrophages, and
serum exceeded the MIC90 (minimum inhibitory concentra-
tion at which the growth of 90% of isolates is inhibited) for
common respiratory pathogens after administration of oral
doses to patients undergoing fiber-optic bronchoscopy
(Andrews et al., 1997). Trovafloxacin is hepatically metab-
olized by conjugation, with 13% of the administered dose
excreted unchanged (Brighty and Gootz, 1997). The effects
of severe cirrhosis on the pharmacokinetics or efficacy of
fluoroquinolones that undergo hepatic metabolism
are unknown.
We previously have shown that cirrhotic rats are more
susceptible than control rats to experimental pneumococcal
pneumonia and secondary bacteremia (Mellencamp and
Preheim, 1991; Preheim et al., 1991, 1992) and that
administration of granulocyte colony-stimulating factor does
not overcome this defect (Preheim et al., 1996). In addition,
we have previously demonstrated that antibiotic pharmaco-
dynamic parameters are an important predictor of response
rate in a rat pneumococcal pneumonia model (Gentry-
Nielsen et al., 2002). The purpose of this study was to
determine 1) the comparative effect of cirrhosis on the
efficacy of representatives from 3 antibiotic classes for the
therapy of experimental pneumococcal pneumonia in our rat
model and 2) the impact of cirrhosis on antibiotic serum
pharmacokinetic and pharmacodynamic parameters and
intrapulmonary antibiotic concentrations.
2. Materials and methods
2.1. Cirrhosis model
Male Sprague-Dawley rats were fed rat chow and water
containing 1.5 mM phenobarbital. When weight reached
200 g, rats were treated weekly by gastric gavage with
increasing doses of carbon tetrachloride (cirrhotic) or
phosphate-buffered saline (PBS; controls) as previously
described (Mellencamp and Preheim, 1991). Rats develop-
ing stable, visible ascites fluid (indicative of uncompen-
sated cirrhosis) were rested for 1 week before use in
experiments with age-matched controls (Mellencamp and
Preheim, 1991).
2.2. Experimental pneumonia
Rats were anesthetized with ether and their tracheas were
surgically exposed. Type 3 pneumococci (ATCC 6303) were
injected transtracheally in 0.3 mL of saline at 10 the
expected lethal dose 50 (2  106 for cirrhotics and 2  107
for controls) as described (Mellencamp and Preheim, 1991).
For survival studies, after antibiotic therapy was initiated
mortality was observed and recorded for 10 days as
described (Preheim et al., 1996).
2.3. Antibiotic treatment
Cirrhotic and control rats received azithromycin
(ZithromaxR, Pfizer, New York, NY; 50 mg/kg), alatro-
floxacin (TrovanR, Pfizer; 50 mg/kg), ceftriaxone
(RocephinR, Roche Pharmaceuticals, Nutley, NJ; 100 mg/
kg), or saline administered subcutaneously twice daily for 5
days beginning 18 h after experimental infection. The MICs
of the study antibiotics for the infecting strain were the
following: azithromycin, 0.25 mg/L; trovafloxacin, 0.19
mg/L, and ceftriaxone, 0.016 mg/L, as determined by E-test
(AB Biodisk, Solna, Sweden). Serum samples for determi-
nation of pharmacokinetic and pharmacodynamic parame-
ters were obtained from additional rats not used in mortality
studies. On the third day of therapy and after the fifth
antibiotic dose, serum samples were obtained at 1, 3, 5, and
12 h. All sera were frozen at 70 8C for antibiotic
concentration determination.
2.4. Peripheral white blood cell counts and blood cultures
Blood was obtained using aseptic puncture of foot veins
under ether anesthesia (Snitily et al., 1991). Cell counts
before and on days 3 and 5 after infection were performed
using a hemacytometer. Differential cell counts were
performed on stained slides (Diff-Quik; Baxter Scientific
Products, McGraw Park, IL). Quantitative bacterial cultures
also were performed on days 3 and 5 after infection.
2.5. Bronchoalveolar lavage
Rats not used in mortality studies were killed by an
intraperitoneal injection of pentobarbital and exsanguinated
by cardiac puncture 1 h after the last antibiotic dose on day
3 of therapy. The lungs and trachea were removed and a
20-gauge catheter was positioned above the carina. Cold
saline was injected into the lungs in 8-mL aliquots
(approximately 60 mL) and recovered by gravity drainage
until a final volume of 50 mL was collected as described
(Preheim et al., 1991). Aliquots of bronchoalveolar lavage
fluid (BALF) were cultured. Cells were collected by
centrifugation, resuspended in PBS, and counted with a
hemacytometer. Differential cell counts were performed on
Diff-Quik–stained cytospin cell preparations.
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2.6. Antibiotic assays
All serum, BALF, and BAL cells collected at steady
state were assayed by high-performance liquid chromatog-
raphy techniques.
Azithromycin concentrations were measured by a
previously published method (Olsen et al., 1996; Shepard
et al., 1994). This reverse-phase assay used an electro-
chemical detector set in a series mode with dual glassy
carbon electrodes at 600 and 800 mV versus Ag–AgCl with
aliquot extracted from the sample matrix injected onto the
column. Quality control samples were assayed with each
standard curve and daily during the analysis. The intra- and
interday percent coefficients of variation were 5.3% and
7.9% for BALF and cell pellets and 4.4% and 5.9% in
serum, respectively.
The concentrations of ceftriaxone in BALF, AM, and
serum were assayed by a high-performance liquid chroma-
tography assay with ultraviolet detection as previously
described (Jehl et al., 1990). The method was validated for
linearity, precision, accuracy, and specificity in our labora-
tory. All samples were prepared before injection on the
column. Briefly, after freeze–thaw cycles of the BAL cells,
acetonitrile, which contains the internal standard (cephalex-
in), was added to BAL cells and serum and deproteinated,
vortexed, and centrifugated. An aliquot of 50 Al of the
supernate was injected onto the column. The BALF samples
were prepared by centrifugation and then filtered through a
0.22-Am filter before extraction and injection onto the
column. Separation was performed with a C18 reverse-phase
column (70  4.6 mm; particle size 3 Am; Phenomix,
Torrance, CA). The mobile phase consisted of 24 mM
hexadecyl trimethylammonium bromide–phosphate buffer
(pH 7.0)–acetonitrile (43:5:52, v/v/v) at a flow rate of 1.5
mL/min at a temperature of 35 8C. The assay was linear over
the range of 0.25–100 Ag/mL with the limit of quantification
set at 0.10 Ag/mL. The inter- and intraday coefficients of
variation were determined for eachmatrix: 7.7% and 3.8% for
serum, 8.0% and 5.2% for BAL cells, and 9.8% and 7.8% for
BALF, respectively.
Trovafloxacin concentrations in all matrixes were deter-
mined by a previously published assay (Teng et al., 1996a,
1996b). This assay used solid-phase extraction and a
reverse-phase chromatography method with ultraviolet
detection. Before extraction, the BAL cells were exposed
to freeze–thaw cycles to release intracellular drug. After the
extraction procedure, supernates of all matrixes containing
the internal standard (trovafloxacin derivative) were sepa-
rated by a C18 analytical column and equivalent guard
column with the wavelength set at 275 nm. The mobile phase
consisted of 0.04 M H3PO4–acetonitrile–terbutylammonium
hydroxide–0.005 M dibutyl amine phosphate reagent
(82:16.9:0.05:0.05, v/v) at pH 3. The lower range of
quantification was 0.1 Ag/mL and was linear over the range
of 0.1–20 Ag/mL for all matrixes. The intra- and interday
coefficients of variation at 1.0 Ag/mL were 4.5% and 5.9%
for serum, 6.7% and 8.6% for BAL cells, and 5.6% and 7.8%
for BALF, respectively.
Albumin and urea concentrations in serum and BALF
were determined by previously described methods (Olsen
et al., 1996). The volume of ELF contained in each BALF
sample was determined by the urea dilution method and
results confirmed by application of the same method with
albumin dilution (Renard et al., 1986). The ELF volume
(VELF) is estimated by the following relationship: VELF =
VBAL  (UreaBAL/Ureaserum), where VBAL is the volume of
BAL fluid, UreaBAL is the urea concentration in the BALF,
and Ureaserum is the concentration of urea in the serum. The
concentration of antibiotic in the ELF (ABXELF) was
determined by the following formula: ABXELF = ABXBAL
/VELF, where the ABXBAL is the total amount of drug in
each BALF sample.
The volume of BAL cells in the cell pellet was
determined by cytocentrifugation and multiplying the mean
cell volume times the total number of BAL cells. The mass
concentration of antibiotic divided by the cell volume
produced a concentration in micrograms of cell volume
(Baldwin et al., 1992; Wilcox et al., 1988).
Separation of free from protein-bound fractions of
azithromycin, ceftriaxone, and trovafloxacin were deter-
mined by an ultrafiltration technique. Briefly, 0.375 mL of
serum from each rat was divided into 2 aliquots, one of
which was inserted into an ultrafiltration device (Amicon,
Beverly, MA) and centrifuged at a fixed angle for 20 min at
1000  g. The resultant ultrafiltrate and the nonfiltered
serum aliquot were then analyzed for the respective anti-
biotics as described. The ratio of the concentration in the
ultrafiltrate to the total concentration in the nonfiltered
sample was used to calculate the antibiotic free fraction. With
each sample run, a blank containing sterile water, a blank
containing mobile phase, and saline with antibiotic spiked at
a midrange concentration were analyzed to confirm no
binding to the filter membrane.
2.7. Pharmacokinetics and pharmacodynamics
Antibiotic serum concentrations versus time were ana-
lyzed with WinNonlin Software, Standard Edition, Version
1.5 (Scientific Consulting, Cary, NC). The azithromycin,
ceftriaxone, and trovafloxacin pharmacokinetic parameters
were estimated using a noncompartmental extravascular
dose input model. The area under the serum concentration
time curve for all antibiotics (AUC0–24) was calculated by
the trapezoidal rule. Pharmacodynamic parameters were
determined by dividing the MIC of the antibiotics for S.
pneumoniae 6303 into the AUC (AUC/MIC) and the
maximum calculated serum concentration (Cmax/MIC).
The percent time that the serum concentration exceeded
the MIC (%T N MIC) was calculated using the equation
Cpmin = Cpmaxd e
ket, where Cpmin equals the MIC, Cpmax
equals the calculated maximum peak serum concentration,
and eket is the decay parameter.
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2.8. Statistical analysis
Mortality statistics were performed by Fisher’s exact test.
White blood cell (WBC) parameters and mean pharmaco-
kinetic parameters were compared by 1-way ANOVA, with
post hoc comparisons determined by Tukey’s and Newman-
Keuls tests, respectively. The level of significance was set at
P b 0.05 for all analyses.
3. Results
3.1. Peripheral white blood cell counts and percentage of
polymorphonuclear leukocytes
Baseline mean peripheral WBC counts before infection
were significantly higher in cirrhotic rats than in controls
when rats from all drug treatment groups were combined
(P = 0.002; Fig. 1). Peripheral WBC counts rose after
infection, peaked on day 5, and returned to baseline at day
10 in cirrhotic and control rats treated with azithromycin.
Similar trends were seen in cirrhotic rats treated with
trovafloxacin. Control rats that received trovafloxacin,
however, maintained elevated peripheral WBC counts
through day 10. In contrast, peripheral WBC counts did
not rise in either cirrhotic or control rats treated with
ceftriaxone (Fig. 1).
The mean percent polymorphonuclear leukocytes
(PMNLs) in peripheral blood also was significantly higher
at baseline in cirrhotic rats from all drug treatment groups
when compared with controls (P b 0.001; Fig. 2A). In
control rats, these percentages rose during infection and
treatment, peaking on day 5 in groups treated with
azithromycin or trovafloxacin and on day 3 in those
receiving ceftriaxone. In cirrhotic rats, mean percent PMNL
remained at baseline serum concentrations through day 5
and fell by day 10 in those receiving azithromycin or
trovafloxacin (Fig. 2B). PMNL counts fell more quickly in
cirrhotic rats treated with ceftriaxone and were significantly
lower at days 3 and 5 in this group compared with other
cirrhotic rats receiving azithromycin or trovafloxacin (P b
0.05; Fig. 2B).
3.2. White blood cell and polymorphonuclear leukocytes in
bronchoalveolar lavage fluid
On day 3 of therapy, there were no significant differences
in the numbers of WBC and PMNL recovered in BALF
from cirrhotic versus control rats (data not shown). There
was a tendency toward higher numbers of PMNL in the
BALF of PBS-treated rats in comparison with those
receiving any of the antibiotics, but these differences also
failed to reach statistical significance.
3.3. Bacteria in bronchoalveolar lavage fluid and
peripheral blood
Three days after infection, control rats treated with any
antibiotic had similar significant reductions of pneumococci
in their BALF cultures when compared with control rats
that were sham-treated with PBS (P b 0.001; data not
shown). The results were similar in antibiotic- and sham-
treated cirrhotic rats. All 3 antibiotics were equally
effective in clearing pneumococci from the lungs when
comparisons were made both within and between cirrhotic
and control groups.
All PBS-treated control and 5 of 8 PBS-treated cirrhotic
rats had N102 CFU/mL of S. pneumoniae in their
bloodstream on day 3. In contrast, blood cultures on day 3
were sterile in all antibiotic treatment groups with the
Fig. 1. Numbers of total peripheral WBCs as determined by hemacytometer count before and after infection. AZI, azithromycin; TROV, trovafloxacin; CEFT,
ceftriaxone; PBS, phosphate-buffered saline.
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exception of 1 control rat receiving trovafloxacin (1.6  103
CFU/mL) and 1 control rat receiving azithromycin (4 
10 CFU/mL).
3.4. Survival
In survival studies, all control rats and 70% of cirrhotic
rats died after sham treatment with PBS (Fig. 3). In
comparison, all of the cirrhotic and control rats treated with
azithromycin, trovafloxacin, or ceftriaxone survived.
3.5. Pharmacokinetics and pharmacodynamics
Pharmacokinetics parameters varied between antibiotics
(Table 1). Cirrhosis increased the free fraction of antibiotic
compared with previous studies and controls (Ellbogen et al.,
Fig. 3. Cumulative percentage survival of rats recorded for 10 days after experimental challenge. Rats were infected on day 0 with type 3 S. pneumoniae (2 
107 CFU for control rats and 2  106 CFU for cirrhotic rats). AZI, azithromycin; TROV, trovafloxacin; CEFT, ceftriaxone; PBS, phosphate-buffered saline.
Fig. 2. Percentage of WBCs that were neutrophils as determined by manual differentials performed on Diff-Quik–stained slides of peripheral blood smears
performed before and after infection. AZI, azithromycin; TROV, trovafloxacin; CEFT, ceftriaxone; PBS, phosphate-buffered saline.
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2003; Gentry-Nielsen et al., 2002; Shepard and Falkner,
1990; Teng et al., 1996a, 1996b). Using the combined data
for cirrhotic and control groups, at 1 h postdose, the mean
serumCmax was highest for ceftriaxone (92.4F 16.1 Ag/mL),
intermediate for trovafloxacin (13.2 F 4.5 Ag/mL), and
lowest for azithromycin (3.4F 0.3 Ag/mL). The free fraction
serumCmax/MIC ratios for the ceftriaxone, azithromycin, and
trovafloxacin antibiotics were 1617, 11.6, and 9.7, respec-
tively (P b 0.05, ceftriaxone vs. azithromycin or trovaflox-
acin). The free fraction AUC/MIC ratios followed a similar
pattern with free fraction values of 1032, 44.2, and 30.8 (P b
0.05 ceftriaxone vs. azithromycin and trovafloxacin).
In contrast to results with serum, ceftriaxone concen-
trations were undetectable in BALF, ELF, or BAL cells
(Table 1). The mean concentrations of azithromycin and
trovafloxacin in BALF were similar (1.7 F 0.8 and 1.2 F
0.9, respectively). This likely represents the short half-life
and lack of ceftriaxone uptake into alveolar macrophages. In
ELF, however, azithromycin achieved significantly higher
concentrations than were observed with trovafloxacin
(44.2 F 18.9 vs. 3.2 F 1.4 mg/L; P b 0.05). Similarly,
the ELF concentration/MIC was higher for azithromycin
than for trovafloxacin (176.8 vs. 16.3; P b 0.01).
Intracellular concentrations of azithromycin exceeded those
of trovafloxacin by approximately 3-fold in WBC obtained
by BAL.
4. Discussion
Cirrhosis increases the susceptibility to and mortality
from severe pneumococcal infections in both humans and
rats. The precise mechanisms are unknown, but cirrhotic rats
demonstrate decreased uptake and killing of pneumococci
by phagocytes within their lungs (Gentry et al., 1996) and
diminished clearance of complement-activating pneumo-
coccal strains from their bloodstream (Alcantara et al.,
1999). However, no published studies to date have
determined whether cirrhosis affects the outcome of
antibiotic therapy for these infections.
Recent guidelines for the treatment of pneumococcal
pneumonia (Mandell et al., 2003) include azithromycin and
advance-generation quinolones such as trovafloxacin, and
ceftriaxone, which are representatives of 3 different classes
of antimicrobials. These agents are highly effective in the
normal host but vary with respect to their pharmacokinetics
and hepatobiliary clearance.
In normal human volunteers, ceftriaxone demonstrates
extensive and saturable protein binding, substantial biliary
clearance, and renal elimination almost exclusively by
glomerular filtration (Patel et al., 1981). In a single-dose
pharmacokinetic study, Stoeckel et al., (1984) found that
when compared with normal controls, patients with chronic
liver disease had significantly decreased mean nonrenal
clearance of unbound ceftriaxone. The elimination half-life
(t1/2b), however, was not influenced by chronic liver
insufficiency (Stoeckel et al., 1984). Others (Hary et al.,
1989) conducted a similar study in cirrhotic patients with
ascites and also found no change in t1/2b. Plasma concen-
trations versus time plots (AUC) of ceftriaxone in healthy
subjects, however, are significantly higher than those in the
cirrhotic patients. The apparent volumes of distribution (Vd)
were higher in patients with liver disease. This finding may
be because of expansion of the extracellular space by the
presence of ascites. Another proposed explanation is
reduction in protein binding of the drug, which would
allow its movement into the extracellular compartment.
Protein binding could be reduced because of decreased
synthesis of albumin and/or the accumulation of endoge-
nous binding inhibitors such as bilirubin (Hary et al., 1989).
The rats in this study demonstrated similar pharmacokinet-
ics to human subjects with cirrhosis with decreased protein
binding among all antibiotics.
Our rat model of CCl4-induced liver cirrhosis is
associated with decreased serum albumin concentration,
elevated serum bilirubin levels, and development of ascites
(Mellencamp and Preheim, 1991). Cirrhotic rats achieved
lower mean peak serum ceftriaxone concentrations com-
pared those observed in control rats, but were not
statistically different. However, the free fraction of antibiotic
did increase because of the reduced protein binding. These
results differ slightly from those observed in the studies with
patient volunteers cited above (Jehl et al., 1990; Mazzei
et al., 1993; Stoeckel et al., 1984). Unlike the single-dose
ceftriaxone pharmacokinetic studies in uninfected cirrhotic
patients, we measured peak serum concentrations at steady
state on day 3 of therapy in rats with pneumococcal
pneumonia. By this time, the infected cirrhotic rats also
Table 1
Pharmacokinetic and pharmacodynamic parameters for ceftriaxone, azi-
thromycin, and trovafloxacin
Mean concentration (mg/L)
Ceftriaxone Azithromycin Trovafloxacin
Cirrhotic rats
Serum Cmax 92.4 F 16.1 3.4 F 0.3* 13.2 F 4.5*
AUC F 59.7 F 10.3 13 F 1.2 41.9 F 8.7
PB (%) 72 F 14.5 15 F 2.4 86 F 3.4
Cmax/MIC
a 1617 F 278 11.6 F 1.1 9.7 F 3.3
%T N MICa 27.6 F 4.8 12.8 F 1.3 1.89 F 0.6
AUC/MICa 1032 F 178 44.2 F 5.2 30.8 F 6.9
BALF 0b 1.7 F 0.8 1.2 F 0.9
ELF 0b 44.2 F 18.9* 3.2 F 1.4
BALF WBC 0b 121.2 F 36.7* 38.4 F 17.1
Control rats
Serum Cmax 106.2 F 18.3 1.2 F 0.2* 16.4 F 5.9*
BALF 0b 1.6 F 0.7 1.1 F 0.9
ELF 0b 36.5 F 14.6* 3.0 F 1.0
BALF WBC 0b 103.2 F 29.8* 33.5 F 13.7
All data are expressed as mean F SD (n = 4).
BALF, bronchoalveolar lavage fluid; ELF, epithelial lining fluid; BALF
WBC, white blood cells from bronchoalveolar lavage fluid.
a Value was calculated using antibiotic free fraction.
b Below level of detection.
* P b 0.05 for comparisons between drugs.
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had reabsorbed some of their ascitic fluid, thus, reducing the
Vd of ceftriaxone. Ceftriaxone demonstrated considerably
higher AUC/MIC and Cmax/MIC ratios as well as the %T N
MIC compared with other study antibiotics. Azithromycin
values were higher than those of trovafloxacin, but only
%T N MIC was statistically different. Although the efficacy
was similar among all agents, in rats given ceftriaxone and
azithromycin, peripheral WBC normalized to baseline
whereas those rats receiving trovafloxacin remain elevated
through study day 10. In previous pharmacodynamic studies
in animal models, fluoroquinolone AUC/MIC ratios greater
than 30 have been associated with efficacy in pneumococcal
pneumonia (Lister and Sanders, 1999; Ambrose et al.,
2001). Trovafloxacin AUC/MIC ratios barely reached the
minimum efficacy value (30.8 F 6.9) and may partially
explain failure of the peripheral WBC to normalize.
Trovafloxacin undergoes primarily phase 2 hepatic
metabolism (glucuronidation, N-acetylation, and N-sulfo-
conjugation) with minimal oxidative metabolism (Vincent
et al., 1998). The drug’s pharmacokinetics do not appear
to be significantly altered in patients who have acute
hepatic dysfunction with elevated liver transaminases
(Garey and Amsden, 1999), but patients with severe
cirrhosis have not been studied. In our rat model, the presence
of cirrhosis did have a small decrease of most pharma-
cokinetic values compared with normal rats (Teng et al.,
1996a, 1996b).
The relative pharmacokinetics of azithromycin, trovaflox-
acin, and ceftriaxone varied widely as expected. Ceftriaxone
reached peak serum concentrations that exceeded by 1–2
logs, respectively (ie, those achieved by trovafloxacin and
azithromycin in both cirrhotic and control rats). In contrast,
ceftriaxone was undetectable in BALF or ELF obtained
minutes after the serum samples were drawn. The MICs for
trovafloxacin and azithromycin against the test strain of
pneumococcus were 10-fold higher than the MIC for
ceftriaxone. The success of azithromycin and trovafloxacin
in this pneumonia model is likely related to multiple factors,
including antibiotic penetration into bronchial secretions and
pulmonary phagocytes, where they achieved concentrations
that were well above their MICs for S. pneumoniae.
The peripheral WBC is commonly used to help
determine the severity of infection and response to therapy
in humans. No rise in peripheral WBC counts was observed
in control or cirrhotic rats treated with ceftriaxone. In
contrast, peripheral WBC counts initially rose before
returning to baseline in those receiving azithromycin or
trovafloxacin. This result may have been because of a more
rapid response to treatment with ceftriaxone, thus averting
the initial leukocytosis after infection. The %T N MIC
pharmacodynamic parameter at approximately 50% of the
dosing interval best describes activity and clinical outcomes
of ceftriaxone and other cephalosporins. However, in this
study, %T N MIC for ceftriaxone exceeded the MIC for
only 27% of the dosing interval, predicting a higher
treatment failure, which we did not observe. At very high
AUC/MIC ratios against pneumococci, ceftriaxone acted in
a concentration-dependent manner in this model. If a
pneumococcal strain with an MIC N 1 had been used,
AUC/MIC ratios would have fallen to b100, making them
more comparable to azithromycin and trovafloxacin. The
persistent elevation in peripheral WBC observed in control
rats treated with trovafloxacin was likely because of an
inflammatory reaction and the minimally acceptable AUC/
MIC ratios required for efficacy. Tender subcutaneous
nodules developed at the injection site where rats received
alatrofloxacin. No nodules were found in rats treated with
ceftriaxone, and only a minimal local reaction to azithro-
mycin was noted. Despite these differences in WBC
responses to therapy, all antibiotics were equally effective
in removing pneumococci from the lung and the blood-
stream. In addition, there was no difference in mortality
among rats in any of the antibiotic treatment groups.
The impact of azithromycin on BALF WBC counts was
not significantly different from what was observed in the
other antibiotic groups. Macrolides, including azithromycin,
possess anti-inflammatory properties that could reduce the
overall number of neutrophils in the respiratory tract
(Yamaryo et al., 2003; Tamaoki, 2004). The macrolide
anti-inflammatory response is generally thought to effect
cytokine production and neutrophil accumulation in nonin-
fected patients and animal models (Tamaoki, 2004). In a
study of azithromycin’s effect on neutrophil function in
healthy human subjects, inflammatory mediators were found
to be reduced, although the circulating WBC did not change
acutely or after 28 days of therapy (Culic et al., 2002). In a
preliminary study in 30 noninfected subjects with stable
chronic obstructive lung disease, clarithromycin therapy
resulted in a reduction of airway neutrophils (Basyigit et al.,
2004). Despite these studies in noninfected patients, the
effect of azithromycin on peripheral and pulmonary neu-
trophils during infection remains largely unknown. The anti-
inflammatory properties of azithromycin did not appear to
blunt the WBC response in our model of acute pneumonia.
In summary, uncompensated cirrhosis has no impact on
the efficacy of azithromycin, trovafloxacin, or ceftriaxone
when administered parenterally in a rat model of pneumo-
coccal pneumonia. These results indicate that, despite their
predisposition to severe pneumococcal infections in cirrhotic
hosts, efficacy does appear to be affected by antibiotic
choice. In this model, azithromycin, ceftriaxone, and trova-
floxacin were equally effective at preventing mortality.
Additional studies are needed to determine whether cirrhosis
affects the pharmacokinetics or efficacy of orally adminis-
tered azithromycin and fluoroquinolones for the treatment of
pneumococcal pneumonia.
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